17677-16-6

Upstream product

• 17677-15-5 1-chloro-3-dodecyloxy-propan-2-ol 
• 76-83-5 trityl chloride 
• 117089-03-9 2,2-dimethyl-4-dodecyloxymethyl-1,3-dioxolane 
• 143-15-7 1-dodecylbromide 
• 100165-14-8 3-dodecyloxypropane-1,2-diol 

Downstream Products

• 106881-92-9 C₄₁H₅₂O₃ 
• 70641-54-2 C₂₇H₅₀NO₆P 
• 106881-97-4 Phosphoric acid 2-benzyloxy-3-dodecyloxy-propyl ester 2-bromo-ethyl ester 
• 73073-46-8 3-(dodecyloxy)-2-hydroxypropyl 2-(trimethylammonio)ethyl phosphate 
• 125001-94-7 2-(benzyloxy)-3-(dodecyloxy)propan-1-ol 

Relevant academic research and scientific papers

Design, synthesis and cytotoxicity of chimeric erlotinib-alkylphospholipid hybrids

Two series of erlotinib-alkylphospholipid hybrids were prepared and evaluated for their antiproliferative activities against a panel of four cell lines representing lung, breast, liver and skin cancers using erlotinib and miltefosine as reference standards. Amide analogs elicited more enhanced cytotoxic activity than analogous esters. Amide derivatives 8d and 8e exhibited promising broad-spectrum antiproliferative activity and higher efficacy than reference erlotinib and miltefosine. Their cellular GI50 values was in the ranges of 24.7–46.9 μM and 26.8–43.1 μM for 8e and 8d respectively. Assay results of the inhibitory activity of the prepared compounds on EGFR kinase reaction and Akt phosphorylation in conjugation with statistical correlation analysis indicated that other mechanisms might contribute to their elicited cytotoxicities. In addition, statistical correlation analysis revealed that mechanisms of elicited cytotoxicities for amide series might be different from ester series. In addition, correlation analysis indicated variations in the mechanisms according to the types of cell line.

STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT

5′-Deuterated nucleosides and nucleotides and modifications thereof are provided for use in medical therapies, including as antiviral, anti-tumor and anti-neoplastic agents. In one embodiment, compounds, methods and uses are provided for the treatment of

Lipid analogs for treating viral infections

A method of treating viral infections, and in particular HIV-1, hepatitis B virus and herpes viruses, is disclosed. The method comprising administering to a subject in need of such treatment an infection-combating amount of a phospholipid or phospholipid derivative.

Method of treating hepatitis virus infections

A method of treating hepatitis virus infection is disclosed. The method comprising administering to a human subject in need of such treatment an effective hepatitis virus-combatting amount of an alkyl lipid or alkyl lipid derivative.

Structure-Activity Relationship in PAF-acether. 3. Hydrophobic Contribution to Agonistic Activity

The synthesis of some selected PAF-acether homologues with an alkoxy-chain length from C1 to C20 in position 1 is described.All agonist activities are closely correlated among themselves and with the calculated fatty-chain hydrophobicity.After a discussio